Shaw LM - Search Results

1

Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.

Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter WZ, Weiner MW, Jack CR Jr, Jagust W, Toga AW, Lee VM, Shaw LM; Alzheimer's Disease Neuroimaging Initiative. Trojanowski JQ, et al. Among authors: shaw lm. Alzheimers Dement. 2010 May;6(3):230-8. doi: 10.1016/j.jalz.2010.03.008. Alzheimers Dement. 2010. PMID: 20451871 Free PMC article. Review.

2

Monitoring of mycophenolic acid in clinical transplantation.

Shaw LM, Pawinski T, Korecka M, Nawrocki A. Shaw LM, et al. Ther Drug Monit. 2002 Feb;24(1):68-73. doi: 10.1097/00007691-200202000-00012. Ther Drug Monit. 2002. PMID: 11805725 Review. No abstract available.

3

Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report.

Jain AK, Venkataramanan R, Fridell JA, Gadomski M, Shaw LM, Ragni M, Korecka M, Fung J. Jain AK, et al. Among authors: shaw lm. Liver Transpl. 2002 Sep;8(9):838-40. doi: 10.1053/jlts.2002.34921. Liver Transpl. 2002. PMID: 12200787 Free article.

4

Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies.

Shaw LM, Korecka M, Venkataramanan R, Goldberg L, Bloom R, Brayman KL. Shaw LM, et al. Am J Transplant. 2003 May;3(5):534-42. doi: 10.1034/j.1600-6143.2003.00079.x. Am J Transplant. 2003. PMID: 12752309 Free article. Review. No abstract available.

5

Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses.

Majewski M, Korecka M, Joergensen J, Fields L, Kossev P, Schuler W, Shaw L, Wasik MA. Majewski M, et al. Transplantation. 2003 May 27;75(10):1710-7. doi: 10.1097/01.TP.0000063934.89714.19. Transplantation. 2003. PMID: 12777861

6

Using established immunosuppressant therapy effectively: lessons from the measurement of mycophenolic acid plasma concentrations.

Shaw LM, Nawrocki A, Korecka M, Solari S, Kang J. Shaw LM, et al. Ther Drug Monit. 2004 Aug;26(4):347-51. doi: 10.1097/00007691-200408000-00002. Ther Drug Monit. 2004. PMID: 15257062 Review.

7

Accidental intravenous colchicine poisoning.

Sussman JS, Brozena SC, Skop N, Korecka M, Shaw LM. Sussman JS, et al. Among authors: shaw lm. Ther Drug Monit. 2004 Dec;26(6):688-92. doi: 10.1097/00007691-200412000-00017. Ther Drug Monit. 2004. PMID: 15570196

8

Sensitive, high throughput HPLC-MS/MS method with on-line sample clean-up for everolimus measurement.

Korecka M, Solari SG, Shaw LM. Korecka M, et al. Among authors: shaw lm. Ther Drug Monit. 2006 Aug;28(4):484-90. doi: 10.1097/00007691-200608000-00002. Ther Drug Monit. 2006. PMID: 16885715

9

Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics.

Shaw LM, Korecka M, Clark CM, Lee VM, Trojanowski JQ. Shaw LM, et al. Nat Rev Drug Discov. 2007 Apr;6(4):295-303. doi: 10.1038/nrd2176. Epub 2007 Mar 9. Nat Rev Drug Discov. 2007. PMID: 17347655 Review.

10

PENN biomarker core of the Alzheimer's disease Neuroimaging Initiative.

Shaw LM. Shaw LM. Neurosignals. 2008;16(1):19-23. doi: 10.1159/000109755. Epub 2007 Dec 5. Neurosignals. 2008. PMID: 18097156 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

725 results

Search Page